Overview of Lung Transplantation

Matthew Ricks Morrell, M.D. Medical Director Lung Transplantation Division of Pulmonary, Allergy and Critical Care





Outline

- Background
- Process/Description
- History
- Mechanisms of Action
- Safety and Tolerability
- Use in Solid-Organ Transplantation
- Preliminary Research

First Lung Transplant

Performed on June 11, 1963 at the University of Mississippi Recipient: non-resectable left lung CA Donor: massive myocardial infarction Treated with azathioprine, prednisone and mediastinal radiation Died due to progressive renal failure and malnutrition Survived 18 days

Hardy, JD, Webb, WR, Dalton, ML Jr, Walker, GR Jr. Lung homotransplantation in man. JAMA 1963; 186:1065

Lung Transplantation History

- 1963-1981: Nearly 40 lung transplants were attempted
 - Longest survival of 6-8 months
 - Complicated by dehiscence, graft failure







Lung Transplant Research

- (TO be submitted	with a protocol de	scribing the rescarch)
PROJECT TITLE:	MENTAL HUMAN LUNG	TRANSPLANTATION
NAME OF PRINCIPAL JOEL D.	COOPER, M.D.	EPARTMENT: SURGERY
INVESTIGATOR:		00M NO: 10-226 EN EXT: 3679
SOURCE OF FUNDING	NE	
(<u>11 hily</u>)	/	
ANTICIPATED DURATION DF RESEARCH:	GHTEEN MONTHS	
		0 0
4- Aug-82		Re Como
DATE	510	SNATURE OF APPLICANT
The research described in t assessed as scientifically	the appended protoc valid.	col has been reviewed and
		Folumon
AUGUST 10, 1982	V	

Selection Criteria

III Selection Criteria

Potential candidates will include patients, preferably under 50 years of age, with end-stage, disabling primary pulmonary pathology. This will include patients with end-stage interstitial lung disease and patients with end-stage primary pulmonary hypertension, who have already experienced at least one syncopal episode. Patients with pulmonary failure due to systemic sclerosis will be considered if there is no evidence for circulating immune complexes. Patients with cystic fibrosis will not be considered. Potential candidates should be individuals who are totally disabled unable to perform any tasks and with limited ability to ambulate. Patients requiring home oxygen because of respiratory symptoms will be included. Patients with chronic infection, previous myocardial infarction, or other major organ failure (other than cor pulmonale) will be excluded. Patients should be judged to have less than six months to live. All

First Successful Single Lung Tx

1983



Tom Hall with wife, Barbara 1st successful lung transplant



Ron Grossman MD

Tom was an incredibly brave guy.....I told him what the odds were. 43 human lung transplants had been done to date. No one survived longer than 6 month and in fact, most never left hospital. I remember like it was yesterday. He told me, "It would be a privilege to be patient 44." 8 May 2011 – Ron Grossman

First Successful Double Lung Tx

1986 – First Bilateral Lung Transplant Toronto: Alex Patterson










Lung Transplant at UPMC

1982: Region's first and world's second heartlung transplant

1985: Region's first single lung transplant

1989: Nation's first pediatric double lung transplant






Bartley Griffith

Surgical Technique


1990: Bilateral sequential double lung transplant








Adult Lung Transplants Number of Transplants by Year and Procedure Type






Adult Lung Transplants Kaplan-Meier Survival by Transplant Type (Transplants: January 1990 – June 2013)



Adapted from: JHLT. 2015 Oct; 34(10): 1264-1277

Adult Lung Transplants Kaplan-Meier Survival by Era (Transplants: January 1990 – June 2013)




Adapted from: JHLT. 2015 Oct; 34(10): 1264-1277

Which of these diagnoses is contraindicated for lung transplantation?

- a) Hypersensitivity pneumonitis
- b) Pulmonary alveolar proteinosis
- c) Bronchoalveolar carcinoma
- d) Silicosis
- e) Scleroderma
- f) LAM
- g) None of the above

Adult Lung Transplants Major Indications by Year (Number)




Adapted from: JHLT. 2015 Oct; 34(10): 1264-1277

Adult Lung Transplants

Indications (Transplants: January 1995 – June 2014)

Diagnosis	SLT (N=16,226)	BLT (N=29,457)	TOTAL (N=45,683)	
COPD/Emphysema	6,826 (42.1%)	7,856 (26.7%)	14,682 (32.1%)	
Idiopathic Pulmonary Fibrosis	5,561 (34.3%)	5,442 (18.5%)	11,003 (24.1%)	
Cystic Fibrosis	228 (1.4%)	7,191 (24.4%)	7,419 (16.2%)	
Alpha-1	792 (4.9%)	1,667 (5.7%)	2,459 (5.4%)	
Idiopathic Pulmonary Arterial Hypertension	91 (0.6%)	1,250 (4.2%)	1,341 (2.9%)	
Pulmonary Fibrosis, Other	758 (4.7%)	1,125 (3.8%)	1,883 (4.1%)	
Bronchiectasis	65 (0.4%)	1,167 (4.0%)	1,232 (2.7%)	
Sarcoidosis	301 (1.9%)	857 (2.9%)	1,158 (2.5%)	
Retransplant: Obliterative Bronchiolitis	338 (2.1%)	440 (1.5%)	778 (1.7%)	
Connective Tissue Disease	200 (1.2%)	481 (1.6%)	681 (1.5%)	
Other	1066 (6.6%)	1981 (6.6%)	3047 (13.2%)	

Adult Lung Transplants Kaplan-Meier Survival by Diagnosis (Transplants: January 1990 – June 2013)




Adapted from: JHLT. 2015 Oct; 34(10): 1264-1277

Which of the following diseases can recur after lung transplantation?


- a) Bronchoalveolar carcinoma
- b) Pulmonary alveolar proteinosis
- c) Sarcoidosis
- d) LAM
- e) Diffuse pan bronchiolitis
- g) All of the above

Adult Lung Transplants

Recipient Age Distribution (Transplants: January 1985 – June 2012)



Adult Lung Transplants Recipient Age Distribution by Era



Which of these patients is NOT appropriate for lung transplantation?

- a) 68 yo female who is a Jehovah's Witness with COPD (FEV1 <25%) with osteoporosis.
- b) 22 yo male with CF colonized with Burkholderia cenocepacia with uncontrolled GERD.
- c) 60 yo female with IPF with single vessel CAD who quit smoking 4 mos ago.
- d) 35 yo female with PH previously on Phen-fen with BMI 34 and history of lymphoma in remission since 2004.

Contraindications for lung transplantation

ABSOLUTE

- Recent malignancy
- History of HIV, Hepatitis B or C with cirrhosis
- Active or recent cigarette smoking, drug abuse or alcohol abuse
- Severe psychiatric illness
- Active infection
- Noncompliance with medical care
- Absence of consistent social network
- Severe deconditioning

<u>RELATIVE</u>

- Age >70
- Obesity BMI>35
- Malnutrition BMI<16
- Presence of end organ damage
- Current use of corticosteroids>prednisone 10mg qday
- Prior thoracic surgery or pleurodeisis
- Invasive ventilation
- High level of preformed antibodies to HLA antigens



BODE Index:

COPD

BODE Index:

 Table 2. Variables and Point Values Used for the Computation of the Body

 Mass Index, Degree of Airflow Obstruction and Dyspnea, and Exercise

 Capacity (BODE) Index.*

Variable	Points on BODE Inc			
	0	1	2	3
FEV1 (% of predicted)†	≥65	50-64	36-49	≤35
Distance walked in 6 min (m)	≥350	250-349	150-249	≤149
MMRC dyspnea scale‡	0–1	2	3	4
Body-mass index§	>21	≤21		

* The cutoff values for the assignment of points are shown for each variable. The total possible values range from 0 to 10. FEV₁ denotes forced expiratory volume in one second.

- [↑] The FEV₁ categories are based on stages identified by the American Thoracic Society.
- Scores on the modified Medical Research Council (MMRC) dyspnea scale can range from 0 to 4, with a score of 4 indicating that the patient is too breathless to leave the house or becomes breathless when dressing or undressing.

§ The values for body-mass index were 0 or 1 because of the inflection point in the inverse relation between survival and body-mass index at a value of 21.

COPD



COPD

BODE Index of 7-10 or: History of hospitalization of exacerbation with PCO2 $\geq 50 \text{mm Hg}$ Pulmonary Hypertension or cor pulmonale FEV1 <20% and ■ DLCO <20% or Homogenous distribution of emphysema




IPF/UIP



IPF/UIP

DLCO <39% predicted</p> ■ FVC decrement of 10% over 6 mo. Period ■ Desaturation <88% on 6-min walk Honeycombing on HRCT



Cystic Fibrosis




Cystic Fibrosis

- FEV1 <30% or rapidly declining lung function
 Increasing oxygen requirements
 Hypercapnea
- Pulmonary hypertension




Pulmonary Hypertension



Pulmonary Hypertension

■ NYHA Class III or IV - Low (350m/1150ft) or declining 6-min walk Failing therapy with IV epoprostenol ■ C.I. <2L/min/m2 RA pressure >15 mm Hg



What pre-transplant factors does NOT affect 1 year mortality?

- a) Pre-transplant diagnosis
- **b**) Mechanical ventilation at the time of transplant
- c) Previous chest surgery
- d) Age
- e) Nutritional status
- f) Degree of hypoxia

Timing of listing




Figure 3: Relative (transplantation/continued waiting) risk of death according to diagnosis

Relative risk of 1-0 (broken line) indicates transplantation risk=waiting risk of mortality.

THE LANCET • Vol 351 • January 3, 1998

Influences on Mortality

TABLE 2. RECIPIENT FACTORS ASSOCIATED WITH INCREASED MORTALITY AT 1 AND 5 YEARS*

- Use of IV inotropes prior to transplantation
- Pretransplant mechanical ventilation
- Hospitalized at time of transplantation
- Prior sternotomy
- Older age (>55 y)

* Derived from multivariate analysis of the International Society of Heart and Lung Transplantation lung-transplant database (1)

What study is not routinely obtained as part of the transplant evaluation?

- a) V/Q scan
- b) Previous microbiological data
- **c**) RUQ ultrasound
- d) Barium swallow
- e) DEXA scan

Evaluation for transplantation

- Complete history and physical examination
- Pulmonary function tests
- **6**-minute walk
- CXR
- CT scan of chest
- V/Q scan
- Previous microbiological data

- Right and left cardiac catheterization
- Transthoracic
 echocardiogram
- Barium swallow
- Mammogram
- Colonoscopy
- DEXA scan
- Labs

Pre-Operative Testing: Labs

- **CBC**
- CMP
- PT/PTT/INR
- Prealbumin
- Thrombotic risk screen
- Arterial blood gas
- HLA Typing
- HLA antibody screen

■ HIV

- Hepatitis B/C
- Serologies
 - CMV, EBV, HSV, VZV, Toxoplasmosis
- ∎ IgG
- Sputum Culture
- Urinalysis (cotinine)
- 24 hour urine collection

Evaluation for transplantation

Transplant pulmonologist Transplant surgeon Nurse coordinator Social Worker Financial specialist Nutritionist



Physical therapist/Pulmonary Rehabilitation Psychiatrist

Lung Allocation

- May 2005: Pts. assigned lung allocation score
 - expected number of days lived during the first year post-transplant
 - expected number of days lived during the first year post-transplant
- Post transplant survival measure waitlist survival measure
- **Score:** 0-100

Implications Post-LAS Model

- Lower median wait time: <5 months</p>
 - Higher LAS = shorter wait time
- Less waitlist mortality
- Unchanged short term outcomes
- Mean LAS scores of transplanted patients increased
 - Older recipients
 - More patients with IPF
 - Higher baseline O2
 - More critically ill patients

■ Mechanical ventilation (8-10% of recipients on ventilator)

Which of these parameters is not included in the lung allocation score?

a) diagnosis
b) LV ejection fraction
c) creatinine
d) BMI
e) %FVC

Lung Allocation Score

- Lung diagnosis Date of birth New York Heart Association Class Assisted ventilation Height and weight Diabetes Supplemental oxygen
- Percent predicted FVC
- Six minute walk distance
- Serum creatinine
- Pulmonary artery systolic pressure
- Mean pulmonary artery pressure

Lung Allocation

TABLE 1. FACTORS INVOLVED IN LUNG ALLOCATION SCORE CALCULATION

Factors Predicting Waitlist Survival (Group)	Factors Predicting Transplant Survival (<i>Group</i>)
Forced vital capacity Pulmonary arterial diastolic pressure (A, C, D) Oxygen requirement at rest (A, C, D) Age Body mass index Diabetes mellitus, insulin-dependent Functional status 6 minute walk distance Mechanical ventilation Diagnosis by group (A, B, C, D)	Forced vital capacity (B, D) Pulmonary capillary wedge pressure (D) Mechanical ventilation Age Creatinine Functioanl Status Diagnosis

Where specified in table, the values entered affect the diagnosis groups as marked. Group A = mostly emphysema; Group B = pulmonary hypertension, idiopathic and congenital heart disease; Group C = septic lung disease (e.g., cystic fibrosis); Group D = interstitial lung disease (e.g., mostly idiopathic pulmonary fibrosis).

Proc Am Thorac Soc Vol 6. pp 13–19, 2009

Which of these patients is an acceptable donor ?

- a) 20 yo male with traumatic brain injury treated for VAP.
- b) 32 yo prison inmate with mild chest contusion and PaO2/FiO2 ratio 275
- c) 47 yo female with 18 pack year history of tobacco
- d) 52 yo male with history of colorectal CA 5 years ago
- e) 57 yo s/p cardiopulmonary arrest for massive PE

DONOR AGE DISTRIBUTION FOR LUNG TRANSPLANTS (1/1985-6/2011)



J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095

ISHLT

2012

Donor Criteria

TABLE 1. STANDARD ("IDEAL") LUNG DONOR CRITERIA

Age < 55 yr Clear serial chest X-ray Normal gas exchange ($Pa_{O_2} > 300 \text{ mm Hg on } F_{IO_2} = 1.0$, PEEP 5 cm H₂O) Absence of chest trauma No evidence of aspiration or sepsis Absence of purulent secretions at bronchoscopy Absence of organisms on sputum gram stain No history of primary pulmonary disease or active pulmonary infection Tobacco history < 20 pack-years ABO compatibility No prior cardiopulmonary surgery Appropriate size match with prospective recipient


Definition of abbreviation: PEEP = positive end-expiratory pressure. Adapted by permission from Reference 15.



Immunosuppression: Induction Agents

Decrease early alloreactivity

- Reduce rejection episodes
- Reduce development of chronic rejection
- Improve overall survival




■ No induction ■IL-2 receptor antagonist ■ ATG

Clin Transplant 2008; 22:603-608

Adult Lung Transplants Induction Immunosuppression

Analysis limited to patients receiving prednisone (Transplants: January 2002 – June 2013)





 There are NO immunosuppressive medications with
 FDA approval for lung transplantation



"I go home today. They cured me using this new miracle drug. I'm afraid it'll be years before it's approved for humans." Immunosuppression: Maintenance Regimens


- Glucocorticoids
 - Prednisone
- Calcineurin inhibitors: decrease IL2 production
 - Tacrolimus
 - Cyclosporine
- Cell-cycle inhibitors
 Azathioprine
 - Mycophenolate mofetil

Which of these medications is associated with tremors?

- a) Cyclosporine
- b) Tacrolimus
- **c**) Azathioprine
- d) Mycophenolate Mofetile) Sirolimus


Glucocorticoids

- Used for maintenance and treatment of rejection
- Initially administered at high doses after transplantation and weaned to baseline
 - Methylprednisolone 500mg-1000mg
 IV qday
 - Prednisone 5-10mg qday
- Side effects: DM, HTN, PUD, osteoporosis, poor wound healing, acne, Cushingoid appearance



Calcineurin Inhibitors: Cyclosporine


- Discovered in 1968; approved in renal transplantation in 1978
- Prevents activation and proliferation of CD4+ T cells through IL-2 pathway (calcineurin)
- Blood levels followed by trough
- Metabolized by cytochrome P450
- Causes renal dysfunction, HTN, hyperlipidemia
- Seizures (PRES), TTP/HUS



Tolypocladium inflatum

Calcineurin Inhibitors: Tacrolimus/FK506

- Antiproliferative agent with resultant decreased IL-2 mediated proliferation of T cells
- Administered orally, sublingually or IV
- Administer separate from fatty meals
- Follow trough level
- Cause renal dysfunction, HTN
- Neurologic complications: Headache, seizures, tremors



Streptomyces tsukubaensis

Which of these medications interacts with the metabolism of tacrolimus/cyclosporine?

- a) Diltiazem
- **b**) Voriconazole
- c) Rifampin
- d) Tenofovir
- e) Erythromycin

Cell-Cycle Inhibitors: Azathioprine

- Prodrug for active compound: 6mercaptopurine
- Halts DNA replication and induces lymphocyte apoptosis
- Given oral or IV
- Caution with concomitant allopurinol
- Leukopenia, hepatotoxicity
- Thiopurine methyl transferase (TPMT): severe myelosuppression

Cell-Cycle Inhibitors: Mycophenolate Mofetil



- Converted to active component, mycophenolic acid
- Inhibits synthesis of guanine nucelotides
- Administered oral or IV
- Can obtain drug level
- Co-administration of antiacids/iron decease bioavailability
- Side effects: diarrhea, GI upset, leukopenia, bone marrow suppression
 - Enteric coated: Myfortic

Sirolimus


- Binds to mammalian target of rapamycin (mTOR)
- Arrests T cells in late G1 phase of cell cycle
- Potent antifibroproliferative agent
 - Poor wound healing
- Used in place of azathioprine/MMF
- Monitor drug levels
- Side effects: HTN, myelosuppression, pulmonary toxicities

MAINTENANCE IMMUNOSUPPRESSION AFTER ALEMTUZUMAB (CAMPATH) INDUCTION

MONTHS	1-12	12-24	>24 & CKD	NOTES:
Prednisone (mg/day)	5 Begin AM post-op day 1	5	5	
Tacrolimus *¤ (blood level) 1 st choice	10-15 (10-12 hour trough)	8-12	6-10	Begin 0.5 mg PO bid. Give 1st dose 6 hours after arrival to ICU
Cyclosporine~¤ (usually Neoral) (blood level)	200-300 (10-12 hour trough)	200-250	100-200	Use if intolerant to Tacrolimus
Cellcept ** (250 mg/tablet)	Begin 750 mg PO bid			Monitor <u>neutropenia;</u> Adjust dose accordingly
Myfortic ** (180 mg/tablet)	Begin 540 mg PO bid			Use if GI intolerance to <u>Cellcept</u>
		OTHER	MEDICATIONS	
Azathioprine Ŧ (WBC>3.5)	1.0 – 2 mg/kg/d			Start 50 mg/day, increase to goal after one week if WBC acceptable and tolerating
Sirolimus + (blood level)			4-12 ⁺⁺ in combination with calcineurin inhibitors	Steady-state concentrations occur 5-7 days after dose change

Adult Lung Transplants Maintenance Immunosuppression at Time of Follow-up

Analysis limited to patients receiving prednisone (Follow-ups: January 2002 – June 2013)





Analysis is limited to patients who were alive at the time of the follow-up

Complications: Primary Graft Dysfunction

- Ischemia-reperfusion injury/Primary graft failure
- End result of multiple insults to graft
- Leading cause of morbidity/mortality in perioperative period
- Worse long-term function and increased chance of developing chronic rejection/bronchiolitis obliterans syndrome

Complications: Primary Graft Dysfunction

TABLE 1. INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION PRIMARY GRAFT DYSFUNCTION GRADING SCHEMA

Grade	Pa _{O2} /FI _{O2}	Radiographic Infiltrates Consistent with Pulmonary Edema
0	>300	Absent
1	>300	Present
2	200-300	Present
3	<200	Present

Proc Am Thorac Soc Vol 6. pp 39-46, 2009

What is the PGD grade?

45 yo female s/p DLTx for CF A/C Ventilation: ■ Vt 450, RR 16, PEEP 5 FIO2 1.0 • Abg: 7.32/58/197 **a**) 0 **b**) 1 **c**) 2 **d**) 3

<u>e</u>) Bad...



TABLE 1. INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION PRIMARY GRAFT DYSFUNCTION GRADING SCHEMA

Grade	Pa_{O_2}/F_{IO_2}	Radiographic Infiltrates Consistent with Pulmonary Edema
0	>300	Absent
1	>300	Present
2	200-300	Present
3	<200	Present

Complications: Primary Graft Dysfunction

TABLE 3. POSSIBLE PRIMARY GRAFT DYSFUNCTION RISK FACTORS


Category	Risk Factor for Primary Graft Dysfunction		
Donor variables (inherent):	Age $>$ 45 yr		
	Age < 21 yr		
	African-American race		
	Female sex		
	History of smoking		
Donor variables (acquired):	Prolonged mechanical ventilation		
	Aspiration		
	Trauma		
	Hemodynamic instability after brain death		
Recipient variables:	Diagnosis of idiopathic pulmonary arterial hypertension		
	Pulmonary arterial hypertension		
	Diagnosis of diffuse parenchymal lung disease		
Operative variables:	Use of cardiopulmonary bypass		
	Blood product transfusion		

Complications: Infections

- Major cause of mortality during first year after transplant
- Increased susceptibility
 - Immunosuppressive medications, exposure to environment, dennervation and lack of ciliary movement and cough reflex
- Associated with chronic graft dysfunction/ rejection

Incidence reduced from donor/recipient screening and antimicrobial prophylaxis


Timing of Infection after Transplantation



NEJM 357;25 pp 2601-2614, 2007

CMV

- Viral syndrome, CMV pneumonitis, Extra pulmonary disease
- CMV-seropositive donor transmits significant viral load to recipients
- CMV-seronegative
 recipients are at higher
 risk for primary infection



Which organ is less likely to be infected with CMV?

a) Eye/retina
b) Lung
c) Liver
d) Stomach
e) Colon

CMV

Incidence 30-86%; reduced due to prophylaxis with Vanganciclovir


Prophylaxis can result in anti-viral resistance

CMV Status	Dose				Duration
	GFR > 60	GFR 40-59	GFR 25-39	GFR 10-24	
D+/R-	900 mg <u>qD</u>	450mg <u>gD</u>	450mg gOD	450mg gMWF	Indefinite or until
D-/R+ or D+/R+	450mg <u>qD</u>	450mg <u>qOD</u>	450mg gMWF	450mg gMTh	6 months
D-/R- or Herpes prophylaxis	450mg gD (consider valacyclovir as substitute to prophylax herpes infections)	450mg <u>gOD</u>	450mg gMWF	450mg gMTh	б months

Pneumocystis

Incidence reduced due to prophylaxis
Trimethoprim-sulfamethoxazole
Dapsone
Atovaquone/Mepron
Inhaled pentamidine

Life long prophylaxis



Fungal Infections


- Colonization, airway infections, dissemination
 - Aspergillus (Airway stent)
 - Candida
 - Rhizopus
 - Rhizomucor

- Mucor
- Scedosporium
- Fusarium
- CT chest useful in distinguishing colonization form infection
- Prophylaxis
 - Reduces risk of invasive disease
 - Duration?


Multi-drug resistant Gram Negative Infections

- More common in cystic fibrosis/chronic rejection
- Acquired via colonization or nosocomially
- Burkholderia cepacia associated with poor transplant outcome
- Inhaled tobramycin






Early Classification of Lung Allograft Dysfunction



Current Classification of Lung Allograft Dysfunction

Timing of Rejection



Proc Am Thorac Soc Vol 6. pp 54-65, 2009


Complications: Acute Cellular Rejection


- Occurs in 90% of recipients
- Asymptomatic to severe hypoxemia and SOB
- Diagnosed by bronchoscopy and transbronchial biopsies
- Associated with development of chronic rejection
- Most episodes respond to high-dose steroids

Pathologic Grading of Lung Rejection

Category 	Grade	Meaning	Appearance	
A: acute rejection	0	None	Normal lung parenchyma	
	1	Minimal	Inconspicuous small mononuclear perivascular infiltrates	
	2	Mild	More frequent, more obvious, perivascular infiltrates, eosinophils may be present	
	3	Moderate	Dense perivascular infiltrates, extension into interstitial space, can involve endothelialitis, eosinophils, and neutrophils	
	4	Severe	Diffuse perivascular, interstitial, and air-space infiltrates with lung injury. Neutrophils may be present.	
B: airway inflammation	0	None	No evidence of bronchiolar inflammation	
	1R	Low grade	Infrequent, scattered or single layer mononuclear cells in bronchiolar submucosa	
	2R	High grade	Larger infiltrates of larger and activated lymphocytes in bronchiolar submucosa. Can involve eosinophils and plasmacytoid cells.	
	х	Ungradable	No bronchiolar tissue available	
C: Chronic airway rejection – obliterative bronchiolitis	0	Absent	If present describes intraluminal airway obliteration with fibrous connective tissue	
	1	Present		

Proc Am Thorac Soc Vol 6. pp 54-65, 2009





Proc Am Thorac Soc Vol 6. pp 54-65, 2009

Which of the following is NOT used to treat acute rejection?

- a) Anti-thymocyte globulin
- **b**) Methylprednisolone
- **c**) Rapamycin
- d) Alemtuzumab
- e) Photopheresis
- f) Prayer
- g) None of the above

Treatment of Rejection

ACR Grade 2 or symptomatic grade 1

- Prednisone 100 mg PO then decrease by 10 mg daily until back to baseline steroid maintenance dose.
- Bronchoscopy with biopsy 2 weeks after completion of taper.
- If no response, discuss with pulmonary transplant MD.

Symptomatic ACR grade 2 or grade 3-4

- Solumedrol 1 gram IV times 3 days (~15 mg/kg/day for weight <50 kg)
- Bronchoscopy with biopsy 2 weeks after treatment
- Start CMV and fungal prophylaxis unless CMV -/-
- Check CMV-PCR weekly for one month after steroid bolus
- If no response, discuss with pulmonary transplant MD.

Persistent or Refractory Rejection - Options

- Thymoglobulin (RATG)
- Alemtuzumab (Campath)
- Sirolimus (Rapamycin)
- Solu-medrol
- Photophoresis
- Total lymphocytic radiation

Which of the follow statements is true regarding chronic rejection?

- a) Chronic rejection is the second most common cause of morbidity and mortality after the first two years after transplantation
- b) The only way to diagnose chronic rejection if by spirometric criteria.
- c) Chronic rejection begins insidiously with symptoms developing later in disease
- d) Bronchoscopic cultures in patients with known chronic rejection are almost always negative

Complications: Chronic Cellular Rejection


- Leading cause of morbidity and mortality
- Has both pathologic and clinical classifications
- Often begins insidiously with symptoms developing later in disease
- Permanent airway colonization with Pseudomonas aeruginosa and Aspergillus fumigatus
- Heterogeneous disease with both alloimune dependent and independent risk factors

Chronic Rejection

Histologic:Obliterative bronchiolitis

Clinical:

- Bronchiolitis obliterans syndrome (BOS)
 - FEV₁ below 80% peak value after transplant
 - BOS stages: 0-p, 1, 2, 3



PRE-BRONCHODILATOR


	Actual	Pred.	%Pred.
SPIROMETRY			
FVC (L)	2.06	3.06	67
FEV1 (L)	0.86	2.68	32
FEV1/FVC (%)	42	88	47
FEF 25-75% (L/sec)	0.24	3.29	7
FEF 50% (L/sec)	0.28	4.59	6
FEF 75% (L/sec)	0.11	1.97	6
FEF Max (L/sec)	2.62	5.64	47
Expiratory Time (sec)	12.76		
FIF Max (L/sec)	2.51		

BOS classification

	Original classification		Current proposition
BOS 0	FEV_1 80% or more of baseline	BOS 0	$FEV_1 > 90\%$ of baseline and $FEF_{25-75} > 75\%$ of baseline
		BOS 0-p	$FEV_1 81\%$ to 90% of baseline <u>and/or</u> $FEF_{25-75} \le 75\%$ of baseline
BOS 1	FEV ₁ 66% to 80% of baseline	BOS 1	FEV ₁ 66% to 80% of baseline
BOS 2	FEV ₁ 51% to 65% of baseline	BOS 2	FEV_1 51% to 65% of baseline
BOS 3	FEV ₁ 50% or less of baseline	BOS 3	FEV ₁ 50% or less of baseline


BOS, bronchiolitis obliterans syndrome; FEF₂₅₋₇₅, mid-expiratory flow rate; FEV₁, forced expiratory volume in 1 second.

Chronic Rejection




Semin Resp Critical Care 2006;27(5): 521-533

Air Trapping in Chronic Rejection



Adult Lung Transplants Freedom from Bronchiolitis Obliterans Syndrome Conditional on Survival to 14 days (Follow-ups: April <u>1994 – June 2013)</u>



Risk Factors for Chronic Rejection

TABLE 2. MULTIVARIABLE COX PROPORTIONAL HAZARDS MODEL OF RISK FACTORS FOR BRONCHIOLITIS OBLITERANS SYNDROME STAGE 1

Variable	RR	95% CI	P Value
Acute rejection grade : A ₂	1.54	1.1-2.1	0.011
Lymphocytic bronchiolitis grade : B ₂	1.61	1.1-2.3	0.008
CARV infection	1.53	0.9-2.6	0.119
PGD Grade:			
PGD 0 (reference)	1.00		
PGD 1	1.68	1.03-2.7	0.037
PGD 2	2.04	1.2-3.4	0.007
PGD 3	2.61	1.5-4.5	< 0.0005

Definition of abbreviations: CARV = community-acquired respiratory virus; CI = confidence interval; PGD = primary graft dysfunction; RR = relative risk. Adapted by permission from Reference 10.

Treatment of Chronic Rejection


- High dose corticosteroids
- Conversion of current immunosuppressive regimen
- Sirolimus
- Antilymphocyte therapy
 Antithymocyte globulin
 Azithromycin
 Total lymph node irradia
- Total lymph node irradiation
- Photopheresis
- Re-transplantation

Humoral Rejection

- Recognized clinical entity in renal/heart transplant
- Recognition of allo-antigens by recipient antibodies
- Detection of HLA antibodies is a risk factor for chronic rejection
 - Screen at routine intervals and when clinically indicated

Humoral Rejection

Stage	Circulating antibody ^b	C4d deposition	Tissue pathology	Graft dysfunction
I: Latent humoral response	+	_	_	_
II: Silent humoral reaction	+	+	-	-
III: Sub-clinical humoral rejection	+	+	+	_
IV: Humoral rejection	+	+	+	+



I Heart Lung Transplant 2009:28(1): 96-100

Humoral Rejection: Treatment

IVIG

- Causes B cell apoptosis and blocks binding of donor-reactive antibodies
- Rituximab: anti-CD20 monoclonal antibody
 - Results in B cell depletion
- Plasmapheresis
 - Removes antibody from circulation
 - Reserve for severe episodes of rejection

Post-transplant Lymphoproliferative Disease

- Incidence of 1.3 to 20%
- Usually occurs in first year after transplant
- Reactivation of EBV
- B-cell involvement
- Involves thorax and abdomen
- Rituximab ± systemic chemotherapy/XRT



Which type of malignancy is the most prevalent in lung transplantation?

a) PTLD
b) Non-small cell lung cancer
c) Colo-rectal cancer
d) Skin cancer
e) Renal cell carcinoma

Medical Complications


- Diabetes mellitus
- Hypertension
- Hyperlipidemia
- Renal dysfunction
- Osteoporosis
- Cytopenias
- Avascular necrosis of femoral head

GERDTremorsMalignancies


Adult Lung Transplants Cumulative Morbidity Rates in <u>Survivors</u> within 1 and 5 Years Post Transplant (Follow-ups: April 1994 – June 2014)

Outcome	Within <u>1 Year</u>	Total number with <u>known</u> <u>response</u>	Within <u>5 Years</u>	Total number with <u>known</u> <u>response</u>	
Hypertension	51.7%	(N=17,813)	80.7%	(N=5,293)	
Renal Dysfunction	22.5%	(N=20,551)	53.3%	(N=7,056)	
Abnormal Creatinine $\leq 2.5 \text{ mg}/\text{dl}$	15.7%		35.3%		
Creatinine > 2.5 mg/dl	5.0%		14.3%		
Chronic Dialysis	1.7%		3.0%		
Renal Transplant	0.1%		0.8%		
Hyperlipidemia	26.2%	(N=18,510)	57.9%	(N=5,643)	
Diabetes	23.0%	(N=20,502)	39.5%	(N=6,941)	
Bronchiolitis Obliterans Syndrome	9.3%	(N=19,348)	41.1%	(N=5,987)	

Adult Lung Transplants Freedom from Severe Renal Dysfunction* (Follow-ups: April 1994 – June 2013)



Factors Affecting Survival



Adapted by ISHLT Registry 2015

Adult Lung Transplants

Cumulative Post Transplant Malignancy Rates in Survivors(Follow-

ups: April 1994 – June 2013)

Malignancy/Type		1-Year Survivors	5-Year Survivors	10-Year Survivors	
No Malignancy		18,644 (96.4%)	5,600 (84.3%)	1,049 (72.2%)	
Malignancy (all types combined)		701 (3.6%)	1,042 (15.7%)	403 (27.8%)	
Malignancy	Skin	237	724	284	
Type*	Lymphoma	261	101	43	
	Other	176	263	113	
Type Not Repo		27	9	0	

Other malignancies reported include: adenocarcinoma (2; 2; 1), bladder (2; 1; 0), lung (2; 4; 0), breast (1; 5; 2); prostate (0; 5; 1), cervical (1; 1; 0); liver (1; 1; 1); colon (1; 1; 0). Numbers in parentheses represent the number of reported cases within each time period.

* Recipients may have experienced more than one type of malignancy so sum of individual malignancy types may be greater than total number with malignancy.



Adult Lung Transplants


Cause of Death (Deaths: January 1992 – June 2013)

Cause of Death	0-30 Days (N = 2,905)	31 Days - 1 Year (N = 5,098)	>1 Year - 3 Years (N = 4,797)	>3 Years - 5 Years (N = 2,746)	>5 Years – 10 Years (N = 3,263)	>10 Years (N = 1,092)
Bronchiolitis	8 (0.3%)	233 (4.6%)	1,230 (25.6%)	804 (29.3%)	806 (24.7%)	219 (20.1%)
Acute Rejection	96 (3.3%)	93 (1.8%)	75 (1.6%)	17 (0.6%)	18 (0.6%)	2 (0.2%)
Lymphoma	1 (0.0%)	114 (2.2%)	84 (1.8%)	42 (1.5%)	60 (1.8%)	35 (3.2%)
Malignancy, Non-Lymphoma	5 (0.2%)	144 (2.8%)	380 (7.9%)	300 (10.9%)	448 (13.7%)	135 (12.4%)
CMV	0	116 (2.3%)	48 (1.0%)	7 (0.3%)	4 (0.1%)	1 (0.1%)
Infection, Non-CMV	550 (18.9%)	1,803 (35.4%)	1,041 (21.7%)	506 (18.4%)	586 (18.0%)	182 (16.7%)
Graft Failure	702 (24.2%)	844 (16.6%)	906 (18.9%)	493 (18.0%)	558 (17.1%)	181 (16.6%)
Cardiovascular	329 (11.3%)	257 (5.0%)	210 (4.4%)	138 (5.0%)	182 (5.6%)	83 (7.6%)
Technical	330 (11.4%)	180 (3.5%)	45 (0.9%)	14 (0.5%)	28 (0.9%)	8 (0.7%)
Other	884 (30.4%)	1,314 (25.8%)	778 (16.2%)	425 (15.5%)	573 (17.6%)	246 (22.5%)




Percentages represent % of deaths in the respective time period

Adult Lung Transplants Functional Status of Surviving Recipients (Follow-ups: March 2005 – June 2013)



Adult Lung Transplants Rehospitalization Post Transplant of Surviving Recipients (Follow-ups: April 1994 – June 2013)



Adult Lung Transplants Employment Status of Surviving Recipients (Follow-ups: April 1994 – June 2013)

